The Management Team currently consists of the CEO, CFO, CBO, CCO, CTO, Head of Manufacturing, Director of Human Resources and General Counsel.

The Board of Directors appoints the CEO and decides on the CEO’s remuneration and other benefits. The CEO is responsible for managing and controlling the Company’s business and day-to-day operations with the aim of securing significant, sustained increase in the value of the company for its shareholders in line with Nanoform’s strategy.

The CEO prepares matters for decision by the Board of Directors and implements the decisions of the Board. The CEO reports to the Board of Directors.

Edward Hæggström
Edward Hæggström
CEO
Read more
Edward Hæggström
Edward Hæggström
CEO

Born 1969. Finnish citizen. Co-founder of Nanoform, CEO and a member of the Management Team since 2015.

Education: Ph.D. degree in applied physics from the University of Helsinki and a Master of Business Administration degree in innovation management from Helsinki University of Technology.

Experience: Dr. Hæggström has, among others, been a professor at the University of Helsinki and Head of the Electronics Research Laboratory within the Department of Physics. He has previously held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University and project leader at the CERN.

Other current positions of trust: Dr. Hæggström is scientific advisor and the Chairman of the Board of Directors of GlucoModicum Oy.

Holdings in the company: 5,409,405 shares and 0 stock options, entitling to same amount of shares in the company.

Albert Hæggström
Albert Hæggström
Chief Financial Officer
Read more
Albert Hæggström
Albert Hæggström
Chief Financial Officer

Born 1971. Finnish citizen. CFO and a member of the Management Team since 2018.

Member of the Board of Directors since 2015

Education: Bachelor of Science degree in economics from Hanken School of Economics in Helsinki.

Experience: Mr. Hæggström has more than 20 years’ experience within finance and investing. Prior roles include senior positions at Alfred Berg, BNP Paribas, Nordea and SEB.

Other current positions of trust: [-]

Holdings in the company: 692,000 shares and 400,000 stock options, entitling to same amount of shares in the company.

Gonçalo Andrade
Gonçalo Andrade
Chief of Business Operations
Read more
Gonçalo Andrade
Gonçalo Andrade
Chief of Business Operations

Born 1978. Portuguese citizen. Chief of Business Operations and a member of the Management Team since 2019.

Education: Ph.D. in biochemistry from Ludwig-Maximilians Universität München and Master of Business Administration from the Catholic University of Portugal.

Experience: Dr. Andrade has served as a member of the Boards of Directors of Senzer Limited, SolasCure Limited, Adapttech Limited, Adapttech S.A., Performetric S.A. and Laserleap S.A.. He was a founding member and member of the management team of Hovione Capital SCR and has, among others, held positions as General Manager at Hovione Capital SCR, Business Development Manager at Hovione Farmaciencia SA, Innovation Unit Manager and Drug Discovery Unit Leader at Bioalvo S.A. and in several scientific research roles at Elan Pharmaceuticals.

Other current positions of trust: Dr. Andrade is the owner of Gafra Limitada.

Holdings in the company: 74,000 shares and 220,000 stock options, entitling to same amount of shares in the company.

Christian Jones
Christian Jones
Chief Commercial Officer
Read more
Christian Jones
Christian Jones
Chief Commercial Officer

Born 1980. British citizen. Chief Commercial Officer and a member of the Management Team since 2018.

Education: Master of Chemistry degree from the University of Leeds. Fellow of the Royal Society of Chemistry.

Experience: Mr. Jones has served as Commercial Director, Innovator Pharma Products and Solutions at Johnson Matthey Plc and was a member of the Senior Leadership Team for the Global Health Sector. Prior to this he was Head of Asia Pacific Sales and member of the Senior Leadership Team at Dr. Reddy’s Global Custom Pharma Solutions business after holding the roles of Associate Director and Manager of Sales and Business Development, Europe. His first commercial role was at Prosonix Ltd, where he led global business development for their proprietary particle engineering technology. Prosonix was later sold to Circassia for £100M.

Other current positions of trust: Mr. Jones is a Member of the Industry and Technology Division Council for the Royal Society of Chemistry and serves on the Advisory Board of Pharma Integrates and Bio Integrates Conferences.

Holdings in the company: 300,000 stock options, entitling to same amount of shares in the company.

Niklas Sandler
Niklas Sandler
Chief Technology Officer
Read more
Niklas Sandler
Niklas Sandler
Chief Technology Officer

Born 1972. Finnish citizen. Chief Technology Officer and member of the Management Team since 2019.

Education: Master of Science and Ph.D. degrees in pharmaceutical technology from the University of Helsinki.

Experience: Dr. Sandler has served as member of the Board of Directors of Åbo Akademi Foundation Research Institute and member of the Leadership Team of Åbo Akademi University. In addition, he has, among others, held the positions of Vice Rector for Research Affairs at Åbo Akademi University, Professor in Pharmaceutical Technology at Åbo Akademi University, Professor in Industrial Pharmacy at the University of Helsinki, Senior Scientist in Pharmaceutical and Analytical Research and Development at AstraZeneca.

Other current positions of trust: Dr. Sandler is Chairman of the Board of the Finnish Pharmaceutical Society, member of the Board of Directors of the Sigrid Juselius Foundation, the Orion Research Foundation, Intelligent Pharmaceutics Oy and SAY Group Oy. In addition, he is the owner, CEO and member of the Board of Directors of Superman Holding Ltd.

Holdings in the company: 290,000 stock options, entitling to same amount of shares in the company.

David Rowe
David Rowe
Head of Manufacturing
Read more
David Rowe
David Rowe
Head of Manufacturing

Born 1967. British citizen. Head of Manufacturing and a member of the Management Team since 2019.

Education: Ph.D. degree in Chemistry from the University of Edinburgh.

Experience: Dr. Rowe has held several positions at GlaxoSmithKline plc including Particle Size Reduction Lead, Platform Expert in the Size Reduction Centre of Excellence, Platform Expert in Micronization & Blending Technologies, Operations Support Manager, Production Projects Manager, Production Team Manager, Improvement Support Manager and Process Chemist at GlaxoSmithKline plc.

Other current positions of trust: [-]

Holdings in the company: 290,000 stock options, entitling to same amount of shares in the company.

Johanna Tuomisto
Johanna Tuomisto
Director of Human Resources
Read more
Johanna Tuomisto
Johanna Tuomisto
Director of Human Resources

Born 1966. Finnish citizen. Director of Human Resources at Nanoform and member of the Management Team since 2021.

Education: Master of Laws (LL.M.) degree from the University of Helsinki, Certified Business Coach.

Experience: Mrs Tuomisto held the position of HR Director, Finland at Thermo Fisher Scientific for over 5 years. She has also previously served as Senior Vice President, Administration at Finnvera Oyj, and as Legal & HR Director and Partner at Evli Bank Plc, among other roles.

Holdings in the company: 50,000 stock options, entitling to same amount of shares in the company.

Peter Hänninen
Peter Hänninen
General Counsel
Read more
Peter Hänninen
Peter Hänninen
General Counsel

Born 1988. Nationality – Finnish citizen. Nanoform’s General Counsel and member of the Management Team since September 2020.

Education: Master of Law degree from the University of Helsinki.

Experience: Peter Hänninen has previously served as an attorney in private practice with Borenius Attorneys. In this role, he focused on advising clients in technology, data protection, and general corporate law, with a particular focus on the life science and healthtech sectors. He also held the position of Legal Counsel at the University of Helsinki.

Other current positions of trust: Peter Hänninen has been a Secretary of the Board of Directors at Nanoform since 2015 and a Member of the Board of Directors at Do Company Oy since 2019.

Holdings in the company: 103,125 shares and 230,000 stock options, entitlement to an equal amount of shares in the company.